Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Valeant acquires Coria Laboratories for $95 million
October 2008
SHARING OPTIONS:

ALISO VIEJO, Calif.—Seeking to expand its dermatology business, Valeant Pharmaceuticals Intl. last month purchased all of the outstanding shares of Coria Laboratories Ltd. from its parent company, DFB Pharmaceuticals Inc., for $95 million. The acquisition will add several dermatology products to Valeant's portfolio, including the CeraVe Skin Care Line; Cloderm Cream for the treatment of dermatoses; Akne-Mycin and Atralin for the treatment of acne; Salex for the treatment of hyperkeratotic skin disorders; and Tetrix Cream for the treatment of hand dermatitis, which is expected to launch later this year. Coria also has several products under development, including line extensions for the CeraVe brand product line. Coria's product line currently has annual net sales of approximately $40 million. DDN

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.